Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review

This article was originally published in The Tan Sheet

Executive Summary

FDA's regulatory framework for removing dangerous dietary supplements from the market under the Dietary Supplement Health & Education Act's "unreasonable risk" standard will be issued shortly by the agency
Advertisement

Related Content

Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
Dingell Challenged To Document Reasons For Supplement Safety Doubts
NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
Ephedra Ban Reaction Cautious From Most In Industry; Overdue, Hatch Says
Ephedra Ban Reaction Cautious From Most In Industry; Overdue, Hatch Says
Ephedra “Black Box” Warning Considered By FDA
Ephedra “Black Box” Warning Considered By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS096319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel